"10.1371_journal.pone.0027861","plos one","2011-11-18T00:00:00Z","Lyubov Chaykovska; Karoline von Websky; Jan Rahnenführer; Markus Alter; Susi Heiden; Holger Fuchs; Frank Runge; Thomas Klein; Berthold Hocher","Charité - Universitätsmedizin Berlin, Center for Cardiovascular Research, Institute for Pharmacology and Toxicology, Berlin, Germany; Institute of Nutritional Science, University of Potsdam, Potsdam-Nuthetal, Germany; Charité - Universitätsmedizin Berlin, Medizinische Klinik für Endokrinologie und Nephrologie, Berlin, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany","Conceived and designed the experiments: TK BH. Performed the experiments: LC KVW JR MA SH HF FR. Analyzed the data: LC TK BH. Contributed reagents/materials/analysis tools: LC KVW JR MA SH HF FR. Wrote the paper: LC TK BH.","The authors have read the journal's policy and have the following conflicts: This study was supported by Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, who played a role in study design, data collection and analysis, decision to publish and preparation of the manuscript. Boehringer Ingelheim Pharma GmbH financially supported the study. Holger Fuchs, Frank Runge, and Thomas Klein are research staff of Boehringer Ingelheim Pharma GmbH & Co. Boehringer Ingelheim Pharma GmbH holds the patent of linagliptin (patent number: WO 2004/018468) and developed this compound. This does not alter the authors′ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2011","11","Lyubov Chaykovska","LC",9,TRUE,2,7,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
